July 13, 2016 - Registration Open for New Frontiers in 3D Cell Culture-based Screening Technologies Conference

Registration Open for New Frontiers in 3D Cell Culture-based Screening Technologies Conference

Schlieren, Switzerland, July 13, 2016 – Inaugural meeting, organized by InSphero AG, NCATS, CAAT, and Promega Corp., to be held Thursday, October 13, 2016 in Baltimore, MD. 

Registration and abstract submission for the inaugural New Frontiers in 3D Cell Culture-based Screening Technologies: Towards greater physiological relevance conference open today via the conference website. Conceived and organized by InSphero AG, the National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), the Centers for Alternatives to Animal Testing (CAAT), and Promega Corp., the conference will feature keynote presentations by Dr. Michael Gottesman of the NIH’s National Cancer Institute’s Center for Cancer Research, and Dr. Thomas Hartung of the Johns Hopkins Bloomberg School of Public Health and Director of CAAT.

The one-day symposium, to be held Thursday, October 13, 2016 at the Johns Hopkins University Charles Commons in Baltimore, Maryland, will feature sessions on drug discovery and toxicology, with invited presentations from Novartis, the Hubrecht Institute, Merck, and the NIH’s National Institute of Environmental Health Sciences (NIEHS). Additional speakers will be selected from attendee abstracts submitted for podium presentation, with abstracts for consideration due by August 1, 2016. Abstracts for poster presentations will be accepted until August 15, 2016.

Dr. Jens Kelm, Chief Scientific Officer of InSphero AG and member of the New Frontiers Scientific Advisory Board, says the conference fills what has been a clear gap in scientific forums by focusing on a global view of 3D cell culture technologies. “The goal of this new conference is to assemble an international forum of leaders in the field of 3D tissue models. We aim to offer a balanced perspective of state-of-the-art systems, their adoption and implementation in drug discovery and safety testing, and potential regulatory hurdles to consider as 3D models become standardized and more mainstream.” Kelm notes that the New Frontiers Conference plans to alternate between US and European host cities on an annual basis.

To register or receive more details about the conference, visit the New Frontiers in 3D Cell Culture-based Screening Technologies website.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

Other News

Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter - Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource